



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: August 25, 2011

To: Primary Clinical Research Associates

From: Sanna McKinzie
Research Protocol Specialist III

Re: **N064B, Randomized Phase II Trial of Panitumumab, Erlotinib, and Gemcitabine vs. Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma**

Attached are updated form(s) for this protocol. Edits are as follows:

CRF Title	Brief Description of Edit
Active Monitoring Recist Measurement Form	<ul style="list-style-type: none">Moved Assessment Date, Measurable Disease and Number of Target Lesions questions so they follow the Overall Response Status Question

If you have any questions, please feel free to contact me.

Enclosure